Corona Remedies Reports 87% OCF to EBITDA Ratio, Eyes Further Acquisitions
Corona Remedies has announced an operating cash flow to EBITDA ratio of around 87%, demonstrating strong cash generation capabilities. The company stated that this robust financial position provides adequate room for pursuing further acquisitions as part of its growth strategy, indicating strong operational efficiency and financial flexibility for strategic expansion.
Corona Remedies announced cash reserves of ₹112 crore as of December 31 and set a growth target of 20-25% CAGR for its Wpladone product over the next three years. The strong cash position provides financial stability to support the company's ambitious growth strategy.